Clinical trials: Stage II Prostate Adenocarcinoma
Prostate Cancer
Mitoxantrone and G-CSF in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with G-CSF may make tumor cells more sensitive to the chemotherapy drug and may kill…
- Trial name
- NCT00003183
- Testing
- filgrastim, mitoxantrone hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 64 people
- Sponsor
- Hope Cancer Institute, Inc.
Metastatic Prostate Cancer
Human Telomerase Reverse Transcriptase Messenger RNA (hTERT mRNA) Transfected Dendritic Cell Vaccines
The purpose of this research is to develop a new and powerful type of immune therapy for prostate cancer patients. This therapy involves vaccinations with special stimulator cells found in the human body called dendritic cells.
- Trial name
- NCT01153113
- Testing
- hTERT mRNA DC
- Sponsor
- University of Florida
Prostate Cancer
C-11 Choline PET-CT Scan in Finding Metastases in Patients With Newly Diagnosed High-Risk Prostate Cancer
RATIONALE: New diagnostic procedures, such as C-11 choline PET-CT scan, may be effective in finding cancer that has spread to the bone and lymph nodes in patients with prostate cancer.
- Trial name
- NCT00804245
- Testing
- needle biopsy, PET-CT scans supplemented with 11C-Choline tracer
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Wake Forest University Health Sciences
Prostate Cancer
Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
RATIONALE: Androgens can cause the growth of prostate cancer cells. Drugs, such as ketoconazole, may stop the adrenal glands from making androgens.
- Trial name
- NCT00460031
- Testing
- ketoconazole, lenalidomide, therapeutic hydrocortisone
- Where
- 6 sites in United States
- Volunteers
- 34 people
- Sponsor
- Case Comprehensive Cancer Center
Prostate Cancer
Docetaxel Compared With Observation in Treating Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00376792
- Testing
- docetaxel, active surveillance, adjuvant therapy
- Where
- 8 sites in Denmark, Finland and 3 more
- Volunteers
- 396 people
- Sponsor
- Scandinavian Prostate Cancer Group
Adenocarcinoma of the Prostate, Bone Metastases
Sipuleucel-T With or Without Radiation Therapy in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer
This randomized phase II trial studies how well giving sipuleucel-T with or without radiation therapy works in treating patients with hormone-resistant metastatic prostate cancer.
- Conditions
- Adenocarcinoma of the Prostate, Bone Metastases, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer
- Trial name
- NCT01807065
- Testing
- sipuleucel-T, external beam radiation therapy, laboratory biomarker analysis
- Where
- 3 sites in United States
- Volunteers
- 51 people
- Sponsor
- City of Hope Medical Center
High Risk Prostate Carcinoma, Localized Prostate Adenocarcinoma
Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer
This phase II trial tests how well pembrolizumab along with standard of care androgen deprivation therapy, with bicalutamide and gonadotropin releasing hormone agonist, and radiotherapy for the treatment of patients with high…
- Conditions
- High Risk Prostate Carcinoma, Localized Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8
- Trial name
- NCT06528210
- Testing
- Gonadotropin Releasing Hormone Agonists and Antagonists, Bicalutamide, Biopsy Procedure
- Sponsor
- OHSU Knight Cancer Institute
Stage II Prostate Adenocarcinoma, Stage III Prostate Adenocarcinoma
68Ga-PSMA-11 PET/MRI in Finding Tumors in Patients With Intermediate or High-Risk Prostate Cancer Undergoing Surgery
This phase 2-3 trial studies the utility of 68-gallium (68Ga)-prostate-specific membrane antigen 11 (PSMA-11) positron emission tomography/magnetic resonance imaging (PET/MRI) to find tumors in patients with prostate cancer who…
- Trial name
- NCT02678351
- Testing
- 68Ga-PSMA-11, Magnetic resonance imaging (MRI), Positron Emission Tomography (PET)
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- Andrei Iagaru
Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer
Lenalidomide and Cyclophosphamide in Treating Patients With Previously Treated Hormone-Refractory Prostate Cancer
This phase I/II trial studies the side effects and best dose of lenalidomide when given together with cyclophosphamide and to see how well they work in treating patients with previously treated hormone-refractory prostate cancer.
- Conditions
- Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer
- Trial name
- NCT01093183
- Testing
- lenalidomide, cyclophosphamide, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Nebraska
Prostate Cancer
Surgery Versus Internal Radiation in Treating Patients With Stage II Prostate Cancer
RATIONALE: Internal radiation uses radioactive material placed directly into or near a tumor to kill tumor cells. It is not yet known whether surgery is more effective than internal radiation in treating prostate cancer.
- Trial name
- NCT00023686
- Testing
- surgery, radiation
- Where
- 36 sites in United States, Canada
- Volunteers
- 190 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7
Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery
This randomized phase II/III trial studies docetaxel, antiandrogen therapy, and radiation therapy to see how well it works compared with antiandrogen therapy and radiation therapy alone in treating patients with prostate cancer…
- Conditions
- Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7, Stage III Prostate Adenocarcinoma AJCC v7
- Trial name
- NCT03070886
- Testing
- Bicalutamide, Degarelix, Docetaxel
- Where
- 313 sites in United States, Canada and 1 more
- Volunteers
- 612 people
- Sponsor
- NRG Oncology
Prostate Cancer
Mitoxantrone Following Surgery in Treating Patients With Prostate Cancer at High Risk for Recurrence
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving chemotherapy after surgery may kill more tumor cells.
- Trial name
- NCT00003858
- Testing
- mitoxantrone hydrochloride
- Sponsor
- Alliance for Clinical Trials in Oncology
Prostate Cancer, Adenocarcinoma of Prostate
Mifepristone (RU-486) in Androgen Independent Prostate Cancer
The purpose of this study is to determine the effects (good and bad) that mifepristone has on patients with androgen independent prostate cancer.
- Trial name
- NCT00140478
- Testing
- Mifepristone
- Where
- 4 sites in United States
- Volunteers
- 48 people
- Sponsor
- Dana-Farber Cancer Institute
Prostate Cancer
Radiation Therapy in Treating Patients With Relapsed Prostate Cancer After Surgery
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. It is not yet known which radiation therapy regimen is more effective in treating patients with relapsed prostate cancer.
- Trial name
- NCT01272050
- Testing
- radiation therapy
- Where
- 28 sites in Belgium, Germany and 1 more
- Volunteers
- 350 people
- Sponsor
- Swiss Cancer Institute
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer
This randomized phase II trial compares enzalutamide with standard androgen deprivation therapy in reducing incidence of metabolic syndrome in patients with prostate cancer that has spread to other places in the body.
- Conditions
- Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT02278185
- Testing
- Enzalutamide, leuprolide acetate, goserelin acetate
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- University of Colorado, Denver
Breast Adenocarcinoma, DS Stage I Plasma Cell Myeloma
Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement
This randomized phase III trial studies two different schedules of zoledronic acid to compare how well they work in reducing bone-related complications in patients with breast cancer, prostate cancer, or multiple myeloma that has…
- Conditions
- Breast Adenocarcinoma, DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, Metastatic Malignant Neoplasm to the Bone
- Trial name
- NCT00869206
- Testing
- zoledronic acid
- Where
- 504 sites in United States, Puerto Rico
- Volunteers
- 1,822 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Prostate Cancer
A Study Evaluating Vaccination of Prostate Cancer Patients With Self Dendritic Cells Expressing MUC1
This study investigates the use of the patients own immune cells to treat prostate cancer. Cells are taken from the patient and grown in the laboratory to become specialized immune cells called dendritic cells.
- Trial name
- MUC1 (NCT00852007)
- Testing
- DC-Tn-MUC1: autologous dendritic cells expressing Tn-MUC1
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Hamilton Health Sciences Corporation
Prostate Adenocarcinoma
Mild Hypofractionation With Proton Therapy or IMRT for Intermediate-Risk Prostate Cancer
This is a study to first establish feasibility of the study and then to register the treatment data of adult patients with a diagnosis of intermediate risk of prostate cancer presenting for definitive radiation treatment with…
- Trial name
- NCT01352429
- Testing
- Proton Therapy, IMRT
- Where
- 2 sites in United States
- Volunteers
- 303 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Prostate Cancer
Selenomethionine and Finasteride Before Surgery or Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer
RATIONALE: Selenomethionine may slow the growth of prostate cancer. Testosterone can cause the growth of prostate cancer cells. Finasteride may fight prostate cancer by lowering the amount of testosterone the body makes.
- Trial name
- NCT00736645
- Testing
- selenomethionine, finasteride
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Roswell Park Cancer Institute
Kidney Cancer
Vaccine Therapy in Treating Patients With Kidney Cancer
RATIONALE: Vaccines made from DNA may make the body build an immune response to kill tumor cells. PURPOSE: This randomized phase I trial is studying the side effects and best dose of vaccine therapy in treating patients with…
- Trial name
- NCT00096629
- Testing
- human prostate-specific membrane antigen plasmid DNA vaccine, mouse prostate-specific membrane antigen plasmid DNA vaccine
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Memorial Sloan Kettering Cancer Center